This marks the first time a bispecific ADC has demonstrated a dual benefit in both PFS and OS within a phase 3 trial for TNBC. While standard chemotherapy options offer limited durability in the ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination ...

Three rounds of chemotherapy later, Topic completed his cancer treatment in Jan. 2026. Over the next six weeks, he'd be ...

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

Researchers evaluated a different chemo regimen in combination with Braftovi and Erbitux, which is already approved with mFOLFOX6.

LOS ANGELES, CA - February 12, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

A mom is suing the UK's National Health Service (NHS) after finding out she underwent six years of chemotherapy without actually needing to. Samantha Smith, from ...